Skip to main content
Have a personal or library account? Click to login
Comparative Efficacy of Different Biologic Agents on Radiographic Progression in Patients with Rheumatoid Arthritis: A Network Meta-Analysis Cover

Comparative Efficacy of Different Biologic Agents on Radiographic Progression in Patients with Rheumatoid Arthritis: A Network Meta-Analysis

By: ,  ,   and    
Open Access
|Nov 2026
Read online

Figures & tables

Fig 1.

Flowchart of the inclusion and exclusion criteria for the literature review.

Table 1.

Basic characteristics of the included studies

ReferencesNumber of examples (OG/CG)Age (OG/CG)Proportion of women (OG/CG)Biological inhibitorObservation group intervention (OG)Control group intervention (CG)Study area
Asano et al. (2024)56/28–/––/–TNFGLMMTXJapan
Blanco et al. (2017)137/13855.9 ± 12.3/55.5 ± 12.179.6%/83.3%IL17SecukinumabPBOUSA
Blanco et al. (2017)138/13851.6 ± 12.4/55.5 ± 12.177.5%/83.3%TcellAbataceptPBOUSA
Breedveld et al. (2004)87/885478.0%TNFInfliximabMTXNetherlands
Breedveld et al. (2018)9/1255.6 ± 12.8/53.0 ± 15.378.0%/92.0%TNFEtanerceptPBONetherlands
Breedveld et al. (2006)268/25751.9 ± 14.0/52.0 ± 13.172.0%/73.9%TNFAdalimumabMTXNetherlands
Buttgereit et al. (2023)31/9652.0 (23–73) /54.5 (25–81)77.4%/76.0%TNFABBV-3373PBOGermany
Cohen et al. (2006)308/20952.2 ± 12.2/52.8 ± 12.681.0%/81.0%BcellRituximabMTXUSA
Cope et al. (2024)110/10348.3 ± 11.6/48.8 ± 10.976.0%/79.0%TcellAbataceptPBOGreat Britain
Deakin et al. (2023)464/23556 (47–66) /59 (51–68)68.0%/73.6%TNFAdalimumabPBOUSA
Dokoupilová et al. (2018)81/8155.1 ± 12.7/54.2 ± 11.082.7%/80.2%IL17SecukinumabPBOGreat Britain
Emery et al. (2014)159/16050.2 ± 11.9/48.6 ± 12.978.6%/83.8%TNFGLMMTXGreat Britain
Fleischmann et al. (2017)384/38649.7 ± 12.2/50.7 ± 13.483.0%/83.0%TNFAdalimumab and MTXPBOUSA
Genovese et al. (2014)37/54–/––/–IL17IxekizumabPBOGreat Britain
Genovese et al. (2008)41/4052.5/57.572.0%/85.0%BcellOcrelizumabPBOGreat Britain
Giles et al. (2020)1538/154261 ± 7/61 ± 888.0%/88.0%IL6TocilizumabEtanerceptGermany
Hetland et al. (2020)203/20055.3 ± 15.3/54.6 ± 14.568.5%/69.5%TNFCertolizumabMTXDenmark
Hetland et al. (2020)204/20054.7 ± 14.4/54.6 ± 14.568.6%/69.5%TcellAbataceptMTXDenmark
Hetland et al. (2020)188/20052.4 ± 14.5/54.6 ± 14.568.6%/69.5%IL6TocilizumabMTXDenmark
Humby et al. (2021)79/8255.5 (47.3–65.1) /55.7 (47.7–65.5)84.0%/76.0%IL6TocilizumabRituximabUSA
Liu et al. (2025)136/6847.0 ± 11.2/47.8 ± 12.186.8%/77.9%IL6TocilizumabMTXUSA
Rech et al. (2024)49/4951 ± 11/49 ± 1363.0%/80.0%TcellAbataceptPBOGermany
Rigby et al. (2012)343/32050.5 ± 11.5/51.8 ± 12.082.5%/77.5%BcellOcrelizumabPBOGermany
Rivellese et al. (2023)34/6655.2 ± 12.8/52.9 ± 14.776.0%/73.0%BcellRituximabTocilizumabGreat Britain
Rubbert-Roth et al. (2020)303/30955.3 ± 11.4/55.8 ± 11.982.2%/81.9%TcellUpadacitinibAbataceptSwitzerland
Smolen et al. (2017)54/5554.6 ± 11.3/51.1 ± 10.677.8%/87.3%IL23GuselkumabMTXUSA
Tak et al. (2012)282/27753.8 ± 11.6/54.2 ± 11.383.7%/77.6%BcellOcrelizumabPBOSwitzerland
Taylor et al. (2023)156/7957.5 ± 10.69/55.5 ± 10.6485.0%/82.0%IL6SarilumabPBOUSA
Weinblatt et al. (2003)67/6257.2 ± 11.4/56.0 ± 10.874.6%/82.3%TNFAdalimumabPBOCanada
Weinblatt et al. (2025)147/56158.0 ± 10.7/55.1 ± 11.386.0%/81.0%IL6SarilumabPBOCanada

[i] Note: Among the biological inhibitors, “TNF,” “IL17,” “Tcell,” “Bcell,” “IL6,” and “L23” represent TNF-i, IL-17 inhibitors, T cell costimulatory modulators, B cell scavengers, IL-6 receptor antagonists, and IL-23 inhibitors, respectively. “Pbo” and “MTX” represent placebo and placebo combined with MTX, respectively. GLM, golimumab; MTX, methotrexate; OG / CG, observation group / control group; PBO, placebo; TNF, tumor necrosis factor.

Table 2.

Results of the literature quality assessment

ReferencesBias in randomized processesBias due to deviation from the planned interventionBias in measurement of the outcomeBias due to missing outcome dataBias in selection of the reported resultOverall risk of bias
Asano et al. (2024)11111Low risk
Blanco et al. (2017)11111Low risk
Blanco et al. (2017)11111Low risk
Breedveld et al. (2004)22121Moderate risk
Breedveld et al. (2018)11111Low risk
Breedveld et al. (2006)11111Low risk
Buttgereit et al. (2023)11111Low risk
Cohen et al. (2006)22121Moderate risk
Cope et al. (2024)11111Low risk
Deakin et al. (2023)11111Low risk
Dokoupilová et al. (2018)11111Low risk
Emery et al. (2014)11111Low risk
Fleischmann et al. (2017)11111Low risk
Genovese et al. (2014)22221Moderate risk
Genovese et al. (2008)22221Moderate risk
Giles et al. (2020)11111Low risk
Hetland et al. (2020)11111Low risk
Hetland et al. (2020)11111Low risk
Hetland et al. (2020)11111Low risk
Humby et al. (2021)22121Moderate risk
Liu et al. (2025)11111Low risk
Rech et al. (2024)11111Low risk
Rigby et al. (2012)22121Moderate risk
Rivellese et al. (2023)22121Moderate risk
Rubbert-Roth et al. (2020)11111Low risk
Smolen et al. (2017)11111Low risk
Tak et al. (2012)22121Moderate risk
Taylor et al. (2023)11111Low risk
Weinblatt et al. (2003)22121Moderate risk
Weinblatt et al. (2025)11111Low risk

[i] Note: Key: 1 = low risk, 2 = medium risk, 3 = high risk.

Fig 2.

Network evidence diagrams for the four outcomes. (A) mTSS; (B) bone erosion score; (C) ACR20; (D) serious adverse reactions. Node size is proportional to the number of participants randomized to that class and line width to the number of direct comparisons. mTSS, modified Total Sharp Score.

Table 3.

Results of a network meta-analysis on the impact of different treatment modalities for RA patients on the mTSS

TNF−15.67 (−17.81, −13.52)−14.99 (−18.11, −11.87)−18.46 (−20.86, −16.06)−13.73 (−16.17, −11.28)−18.14 (−21.11, −15.16)
15.67 (13.52, 17.81)IL170.68 (−3.07, 4.42)−2.79 (−5.75, 0.16)1.94 (−1.06, 4.94)−2.47 (−5.63, 0.68)
14.99 (11.87, 18.11)−0.68 (−4.42, 3.07)Tcell−3.47 (−7.12, 0.17)1.26 (−2.68, 5.20)−3.15 (−7.41, 1.11)
18.46 (16.06, 20.86)2.79 (−0.16, 5.75)3.47 (−0.17, 7.12)Bcell4.73 (1.42, 8.04)0.32 (−3.17, 3.82)
13.73 (11.28, 16.17)−1.94 (−4.94, 1.06)−1.26 (−5.20, 2.68)−4.73 (−8.04, −1.42)IL6−4.41 (−7.71, −1.11)
18.14 (15.16, 21.11)2.47 (−0.68, 5.63)3.15 (−1.11, 7.41)–0.32 (−3.82, 3.17)4.41 (1.11, 7.71)IL23

[i] mTSS, modified Total Sharp Score; RA, rheumatoid arthritis; TNF, tumor necrosis factor.

Fig 3.

Cumulative probability plot showing the effect of different treatment approaches on mTSS in patients with RA. mTSS, modified Total Sharp Score; MTX, methotrexate; PBO, placebo; RA, rheumatoid arthritis; TNF, tumor necrosis factor.

Table 4.

Results of a network meta-analysis on the effects of different treatment modalities on bone erosion scores in patients with RA

TNFIL17TcellBcellIL6IL23
TNF−0.29 (−0.49, −0.09)−0.17 (−0.33, −0.01)−0.26 (−0.38, −0.14)−0.22 (−0.40, −0.05)−0.18 (−0.37, 0.02)
0.29 (0.09, 0.49)IL170.12 (−0.14, 0.38)0.03 (−0.20, 0.27)0.07 (−0.15, 0.29)0.11 (−0.14, 0.37)
0.17 (0.01, 0.33)−0.12 (−0.38, 0.14)Tcell−0.09 (−0.27, 0.09)−0.05 (−0.29, 0.19)−0.01 (−0.26, 0.25)
0.26 (0.14, 0.38)−0.03 (−0.27, 0.20)0.09 (−0.09, 0.27)Bcell0.03 (−0.18, 0.25)0.08 (−0.15, 0.31)
0.22 (0.05, 0.40)−0.07 (−0.29, 0.15)0.05 (−0.19, 0.29)−0.03 (−0.25, 0.18)IL60.05 (−0.15, 0.24)
0.18 (–0.02, 0.37)−0.11 (−0.37, 0.14)0.01 (−0.25, 0.26)−0.08 (−0.31, 0.15)−0.05 (−0.24, 0.15)IL23

[i] IL, interleukin; RA, rheumatoid arthritis; TNF, tumor necrosis factor.

Fig 4.

Cumulative probability plot showing the effect of different treatment modalities on bone erosion scores in patients with RA. MTX, methotrexate; RA, rheumatoid arthritis; TNF, tumor necrosis factor.

Table 5.

Results of a network meta-analysis on the impact of different treatment modalities on ACR20 in patients with RA

TNF1.86 (1.08, 3.20)1.30 (0.65, 2.61)1.12 (0.41, 3.08)2.12 (1.20, 3.72)2.75 (1.31, 5.76)
0.54 (0.31, 0.93)IL170.70 (0.29, 1.69)0.61 (0.19, 1.90)1.14 (0.55, 2.35)1.48 (0.73, 3.00)
0.77 (0.38, 1.54)1.42 (0.59, 3.44)Tcell0.86 (0.31, 2.43)1.63 (0.66, 3.98)2.11 (0.76, 5.82)
0.89 (0.32, 2.44)1.65 (0.53, 5.18)1.16 (0.41, 3.27)Bcell1.88 (0.59, 5.98)2.44 (0.70, 8.53)
0.47 (0.27, 0.83)0.88 (0.43, 1.81)0.62 (0.25, 1.51)0.53 (0.17, 1.68)IL61.30 (0.54, 3.12)
0.36 (0.17, 0.76)0.68 (0.33, 1.37)0.47 (0.17, 1.31)0.41 (0.12, 1.43)0.77 (0.32, 1.85)IL23

[i] IL, interleukin; RA, rheumatoid arthritis; TNF, tumor necrosis factor.

Fig 5.

Cumulative probability plot showing the effect of different treatment approaches on ACR20 in patients with RA. MTX, methotrexate; RA, rheumatoid arthritis; TNF, tumor necrosis factor.

Table 6.

Results of a network meta-analysis on the impact of different treatment modalities for RA patients on serious adverse reactions

T cell1.10 (0.43, 2.78)0.75 (0.28, 2.02)1.36 (0.47, 3.98)1.17 (0.42, 3.31)0.87 (0.34, 2.21)
0.91 (0.36, 2.32)TNF0.68 (0.43, 1.08)1.24 (0.64, 2.41)1.07 (0.59, 1.94)0.79 (0.45, 1.39)
1.34 (0.50, 3.63)1.47 (0.93, 2.33)IL61.83 (1.05, 3.20)1.57 (0.96, 2.58)1.17 (0.65, 2.11)
0.73 (0.25, 2.14)0.80 (0.42, 1.55)0.55 (0.31, 0.96)IL230.86 (0.49, 1.51)0.64 (0.33, 1.24)
0.85 (0.30, 2.41)0.94 (0.52, 1.70)0.64 (0.39, 1.05)1.16 (0.66, 2.05)IL170.74 (0.40, 1.38)
1.15 (0.45, 2.91)1.26 (0.72, 2.21)0.86 (0.47, 1.55)1.57 (0.81, 3.03)1.34 (0.73, 2.49)Bcell

[i] IL, interleukin; RA, rheumatoid arthritis; TNF, tumor necrosis factor.

Fig 6.

Cumulative probability plot showing the impact of different treatment approaches on serious adverse reactions in patients with RA. RA, rheumatoid arthritis; TNF, tumor necrosis factor.

Fig 7.

Publication bias funnel plots. (A) mTSS; (B) bone erosion score; (C) ACR20; (D) serious adverse reactions. mTSS, modified Total Sharp Score.

Supplementary Table S1.

Full electronic search strategies

Platform/interfaceDate searchedCoverage (from – to)Limits or filters appliedSearch strategy
PubMed/MEDLINEMarch 20, 2026inception – 31 Dec 2025None#1 “Arthritis, Rheumatoid”[MeSH] OR “rheumatoid arthritis”[tiab] OR “RA”[tiab]
#2 “Biological Products”[MeSH] OR “Antirheumatic Agents”[MeSH] OR biologic*[tiab] OR bDMARD*[tiab] OR “tumor necrosis factor inhibitor*”[tiab] OR adalimumab[tiab] OR etanercept[tiab] OR infliximab[tiab] OR certolizumab[tiab] OR golimumab[tiab] OR tocilizumab[tiab] OR sarilumab[tiab] OR abatacept[tiab] OR rituximab[tiab] OR ocrelizumab[tiab] OR secukinumab[tiab] OR ixekizumab[tiab] OR guselkumab[tiab]
#3 “randomized controlled trial”[pt] OR randomi*[tiab] OR “Radiography”[MeSH] OR “Sharp score”[tiab] OR “van der Heijde”[tiab] OR “joint space narrowing”[tiab] OR “bone erosion”[tiab]
#1 AND #2 AND #3
EmbaseMarch 20, 2026inception – 31 Dec 2025None#1 ‘rheumatoid arthritis’/exp OR ‘rheumatoid arthritis’:ti,ab OR ‘ra’:ti,ab
#2 ‘biological product’/exp OR ‘antirheumatic agent’/exp OR biologic*:ti,ab OR bdmard*:ti,ab OR ‘tumor necrosis factor inhibitor*’:ti,ab OR adalimumab:ti,ab OR etanercept:ti,ab OR infliximab:ti,ab OR certolizumab:ti,ab OR golimumab:ti,ab OR tocilizumab:ti,ab OR sarilumab:ti,ab OR abatacept:ti,ab OR rituximab:ti,ab OR ocrelizumab:ti,ab OR secukinumab:ti,ab OR ixekizumab:ti,ab OR guselkumab:ti,ab
#3 ‘randomized controlled trial’/exp OR randomi*:ti,ab OR ‘radiography’/exp OR ‘sharp score’:ti,ab OR ‘van der heijde’:ti,ab OR ‘joint space narrowing’:ti,ab OR ‘bone erosion’:ti,ab
#1 AND #2 AND #3
Web of Science Core CollectionMarch 20, 2026inception – 31 Dec 2025None#1 TS = (“rheumatoid arthritis” OR “RA”)
#2 TS = (biologic* OR bDMARD* OR “tumor necrosis factor inhibitor*” OR adalimumab OR etanercept OR infliximab OR certolizumab OR golimumab OR tocilizumab OR sarilumab OR abatacept OR rituximab OR ocrelizumab OR secukinumab OR ixekizumab OR guselkumab)
#3 TS = (randomi* OR “randomized controlled trial”) OR TS = (“Sharp score” OR “van der Heijde” OR “joint space narrowing” OR “bone erosion”)
#1 AND #2 AND #3
CENTRALMarch 20, 2026inception – 31 Dec 2025None#1 MeSH descriptor: [Arthritis, Rheumatoid] explode all trees OR (“rheumatoid arthritis” OR “RA”):ti,ab
#2 MeSH descriptor: [Biological Products] explode all trees OR MeSH descriptor: [Antirheumatic Agents] explode all trees OR (biologic* OR bDMARD* OR “tumor necrosis factor inhibitor*” OR adalimumab OR etanercept OR infliximab OR certolizumab OR golimumab OR tocilizumab OR sarilumab OR abatacept OR rituximab OR ocrelizumab OR secukinumab OR ixekizumab OR guselkumab):ti,ab
#3 (“randomized controlled trial”):pt OR randomi*:ti,ab OR MeSH descriptor: [Radiography] explode all trees OR (“Sharp score” OR “van der Heijde” OR “joint space narrowing” OR “bone erosion”):ti,ab
#1 AND #2 AND #3

[i] CENTRAL, Cochrane Central Register of Controlled Trials.

Language: English
Submitted on: May 6, 2026
Accepted on: Sep 8, 2026
Published on: Nov 10, 2026
Published by: Hirszfeld Institute of Immunology and Experimental Therapy
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year

© 2026 Di Liu, Na Yuan, Guimei Yu, Daqing Nie, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution 4.0 License.